WO2004005341A3 - Full-length interferon gamma polypeptide variants - Google Patents

Full-length interferon gamma polypeptide variants Download PDF

Info

Publication number
WO2004005341A3
WO2004005341A3 PCT/DK2003/000426 DK0300426W WO2004005341A3 WO 2004005341 A3 WO2004005341 A3 WO 2004005341A3 DK 0300426 W DK0300426 W DK 0300426W WO 2004005341 A3 WO2004005341 A3 WO 2004005341A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon gamma
full
polypeptide variants
length interferon
gamma polypeptide
Prior art date
Application number
PCT/DK2003/000426
Other languages
French (fr)
Other versions
WO2004005341A2 (en
Inventor
Den Hazel Bart Van
Anne Dam Jensen
Frank Bech Nygaard
Kim Vilbour Andersen
Original Assignee
Maxygen Holdings Ltd
Den Hazel Bart Van
Anne Dam Jensen
Frank Bech Nygaard
Kim Vilbour Andersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd, Den Hazel Bart Van, Anne Dam Jensen, Frank Bech Nygaard, Kim Vilbour Andersen filed Critical Maxygen Holdings Ltd
Priority to EP03732252A priority Critical patent/EP1539814A2/en
Priority to CA002491178A priority patent/CA2491178A1/en
Priority to AU2003239774A priority patent/AU2003239774A1/en
Priority to US10/521,008 priority patent/US7524931B2/en
Publication of WO2004005341A2 publication Critical patent/WO2004005341A2/en
Publication of WO2004005341A3 publication Critical patent/WO2004005341A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The variant comprises at least one amino acid substitution in one of the positions S132 and S142, and at least one amino acid substitution in one of the positions R137, R139 and R140. Alternatively, the variant comprises at least amino acid substitutions in positions R137 and R140. The full-length interferon gamma polypeptide variants of the invention are useful in therapy, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis.
PCT/DK2003/000426 2002-07-03 2003-06-23 Full-length interferon gamma polypeptide variants WO2004005341A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03732252A EP1539814A2 (en) 2002-07-03 2003-06-23 Full-length interferon gamma polypeptide variants
CA002491178A CA2491178A1 (en) 2002-07-03 2003-06-23 Full-length interferon gamma polypeptide variants
AU2003239774A AU2003239774A1 (en) 2002-07-03 2003-06-23 Full-length interferon gamma polypeptide variants
US10/521,008 US7524931B2 (en) 2002-07-03 2003-06-23 Full-length interferon gamma polypeptide variants

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39412002P 2002-07-03 2002-07-03
US60/394,120 2002-07-03
US41521402P 2002-09-30 2002-09-30
US60/415,214 2002-09-30
US41739902P 2002-10-09 2002-10-09
US60/417,399 2002-10-09

Publications (2)

Publication Number Publication Date
WO2004005341A2 WO2004005341A2 (en) 2004-01-15
WO2004005341A3 true WO2004005341A3 (en) 2004-02-26

Family

ID=30119133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000426 WO2004005341A2 (en) 2002-07-03 2003-06-23 Full-length interferon gamma polypeptide variants

Country Status (5)

Country Link
US (1) US7524931B2 (en)
EP (1) EP1539814A2 (en)
AU (1) AU2003239774A1 (en)
CA (1) CA2491178A1 (en)
WO (1) WO2004005341A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
KR20130019457A (en) 2004-07-26 2013-02-26 다우 글로벌 테크놀로지스 엘엘씨 Process for improved protein expression by strain engineering
JP2009529027A (en) * 2006-03-08 2009-08-13 ビオメトード Human interferon gamma (IFNγ) mutant
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101688213A (en) 2007-04-27 2010-03-31 陶氏环球技术公司 Be used for rapidly screening microbial hosts to identify some method at the bacterial strain of output that has improvement aspect the expressing heterologous protein and/or quality
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
WO2023182947A1 (en) * 2022-03-22 2023-09-28 Chiang Mai University A modified protein of interferon gamma and its use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2001036001A2 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd Interferon gamma conjugates

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
JPS58110548A (en) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd Novel physiologically active peptide
EP0088540A3 (en) 1982-02-22 1984-10-17 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4835256A (en) * 1982-09-30 1989-05-30 New York University & Juridical Foundation Human gamma interferon polypeptide having glutamine as the ninth n-terminal amino acid
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
JPH0740925B2 (en) 1983-03-14 1995-05-10 協和醗酵工業株式会社 Novel human interferon-γ polypeptide
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
JPH0788398B2 (en) 1983-10-17 1995-09-27 サントリー株式会社 Novel bioactive polypeptide and method for producing the same
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (en) * 1983-12-16 1992-07-01 Genentech Inc RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING.
DK168016B1 (en) * 1983-12-26 1994-01-17 Kyowa Hakko Kogyo Kk DERIVATIVE OF HUMANT INTERFERON-GAMMA POLYPEPTIDE
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3414831A1 (en) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt PRODUCTION OF POLYPEPTIDES WITH HUMAN GAMMA INTERFERON ACTIVITY
US4921698A (en) * 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
JPS6124599A (en) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd Novel human interferon-gamma polypeptide derivative
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
JP2524586B2 (en) 1985-06-26 1996-08-14 シタス コーポレイション Solubilization of proteins for pharmaceutical compositions utilizing polymer conjugation
DE3536939A1 (en) 1985-10-17 1987-04-23 Hoechst Ag BIOLOGICALLY ACTIVE DERIVATIVES OF HUMAN (GAMMA) INTERFERON, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES
JP2514950B2 (en) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
GB8619725D0 (en) 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) * 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (en) * 1986-12-27 1997-09-10 武田薬品工業株式会社 Novel polypeptide and method for producing the same
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
DE3730331A1 (en) 1987-09-10 1989-03-30 Basf Ag NEW POLYPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, THE VECTORS THEREFOR AND MEDICINAL PRODUCTS THEREOF
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
BG52073B2 (en) 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
US5241072A (en) 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
JPH06501001A (en) 1990-08-31 1994-01-27 シェリング・コーポレーション Human interferon-γ4-134, functional equivalents thereof and uses and compositions of these substances
DE4036856C1 (en) 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
KR950014915B1 (en) 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JPH0770195A (en) * 1993-08-23 1995-03-14 Yutaka Mizushima Sugar-modified interferon
PT730470E (en) * 1993-11-10 2002-08-30 Enzon Inc IMPROVED INTERFERENCE-POLYMER CONJUGATES
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
DE19535853C2 (en) * 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Variants of recombinant human interferon gamma, process for their preparation and their use
EP0795332B1 (en) 1996-03-14 2005-06-01 Mondobiotech Interferon SA Medical use of gamma-interferon in interstitial lung diseases
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
JP2003510295A (en) 1999-09-28 2003-03-18 アマリロ バイオサイエンシズ，インコーポレイテッド Low dose IFN gamma for the treatment of disease
EP1401792A1 (en) * 2001-05-25 2004-03-31 Shell Internationale Researchmaatschappij B.V. Process for the preparation of linear olefins and use thereof to prepare linear alcohols

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2001036001A2 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd Interferon gamma conjugates

Also Published As

Publication number Publication date
EP1539814A2 (en) 2005-06-15
WO2004005341A2 (en) 2004-01-15
US20060099175A1 (en) 2006-05-11
US7524931B2 (en) 2009-04-28
AU2003239774A1 (en) 2004-01-23
CA2491178A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
HUP0203409A2 (en) Interferon gamma conjugates
Hasnain et al. Characterization of recombinant rat cathepsin B and nonglycosylated mutants expressed in yeast. New insights into the pH dependence of cathepsin B-catalyzed hydrolyses.
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
WO2005115306A3 (en) Keratin-binding polypeptides
WO2005019256A3 (en) Muteins of tear lipocalin
EA200700533A1 (en) MUTANT PROTEINS (MUTEINS) OF FIBROBLAST GROWTH FACTOR 21
WO2003059934A3 (en) Albumin fusion proteins
JP2008522617A5 (en)
AU3368497A (en) Human dnase i hyperactive variants
WO2005077042A3 (en) Albumin fusion proteins
WO2000049040A3 (en) Antimicrobial/endotoxin neutralizing polypeptide
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO2004005341A3 (en) Full-length interferon gamma polypeptide variants
BG106051A (en) MUTATIONS OF THE ENDOTHELIUM NITROGEN OXIDE SYNTHETASIS, eNOS AND THIEIR APPLICATION FOR GENE THERAPY AND THRAPEUTIC SCREENING
WO2002081507A3 (en) Interferon gamma polypeptide variants
WO2004018633A3 (en) Abca13 nucleic acids and proteins, and uses thereof
WO2008041014A3 (en) Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2006032909A3 (en) Pka ii anchoring disruption polypeptide
NZ504327A (en) Gene expressed in hypothalamus of obese animals and pharmaceutical use
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
Kakizawa et al. Evaluation of superior BACE1 cleavage sequences containing unnatural amino acids
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2005071070A3 (en) Substances directed against specific sequence essential for heparanase catalytic activity end uses thereof as heparanase inhibitors
GB0120022D0 (en) Conjugate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004562024

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2491178

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003239774

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003732252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003732252

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006099175

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10521008

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10521008

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)